Frontiers in Allergy (Jul 2022)

Efficacy and safety of omalizumab therapy in urticaria vasculitis

  • Fiorella Petrelli,
  • Daiana Giannini,
  • Silvia Bilia,
  • Isabella Del Corso,
  • Valeria Rocchi,
  • Paola Migliorini,
  • Ilaria Puxeddu

DOI
https://doi.org/10.3389/falgy.2022.952079
Journal volume & issue
Vol. 3

Abstract

Read online

Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV.

Keywords